Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

December 16, 2020 By The ASCO Post Staff

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01).

Editor's note: On March 22, 2021, Odonate Therapeutics announced it was discontinuing the development of tesetaxel and will close the company's operations. Read more here.

 

Related Content